ARCHIVES

FDA Advisory Committee Recommends Approval Of Ifosfamide as Third Line Therapy For Testicular Cancer

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer.

March 24, 2006

INSPIRE Enrollment Stopped; Thromboembolism Risk Cited

February 25, 2011

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007

Program Announcements

August 3, 2001

ACS Funds $54 Million in Grants

June 28, 2002

NIH Director Collins Challenged On Capitol Hill Over NCI-Funded Research Linking Tea Party With Tobacco Companies

March 8, 2013